While the median PFS in patients with BRAF-mutated melanoma was 16.8 months with NIVO plus IPI, 5.6 months with NIVO, and 3.4 months with IPI, median PFS in patients with BRAF wild-type was 11.2 months, 8.2 months, and 2.8 months, respectively. This evidence concerns the gene BRAF and melanoma.